SETININ 50 mg Rumunia - rumuński - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

setinin 50 mg

actavis group ptc ehf. - quetiapinum - compr. elib. prel. - 50mg - antipsihotice diazepine, oxazepine si tiazepine

SETININ 200 mg Rumunia - rumuński - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

setinin 200 mg

actavis group ptc ehf. - quetiapinum - compr. elib. prel. - 200mg - antipsihotice diazepine, oxazepine si tiazepine

SETININ 300 mg Rumunia - rumuński - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

setinin 300 mg

actavis group ptc ehf. - quetiapinum - compr. elib. prel. - 300mg - antipsihotice diazepine, oxazepine si tiazepine

SETININ 400 mg Rumunia - rumuński - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

setinin 400 mg

actavis group ptc ehf. - quetiapinum - compr. elib. prel. - 400mg - antipsihotice diazepine, oxazepine si tiazepine

Victrelis Unia Europejska - rumuński - EMA (European Medicines Agency)

victrelis

merck sharp dohme ltd - boceprevir - hepatita c, cronică - antivirale pentru uz sistemic - victrelis este indicat pentru tratamentul hepatitei c cronice (chc) genotip-1 infecţie, în asociere cu interferon alfa şi ribavirină, la pacienţii adulţi cu boli hepatice compensate care sunt netratat anterior sau care au eşuat anterioare terapie.

Evusheld Unia Europejska - rumuński - EMA (European Medicines Agency)

evusheld

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Tremfya Unia Europejska - rumuński - EMA (European Medicines Agency)

tremfya

janssen-cilag international nv - guselkumab - psoriazis - imunosupresoare - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.